Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 8/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047876 | 0.77 | CTSS (0.56) | PKMSMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL5523635 | 0.72 | PKM (0.48) | PKMSMN1; SMN2CTSSCTSLALDH1A1 | |
| SCHEMBL8396994 | 0.72 | HTT (0.72) | PKMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL30423567 | 0.72 | HTT (0.72) | PKMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL8392442 | 0.72 | HTT (0.72) | PKMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL27652120 | 0.70 | PKM (0.49) | PKMSMN1; SMN2CTSSCTSLALDH1A1 | |
| SCHEMBL8395012 | 0.70 | HTT (0.69) | PKMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| Bicarbonate SCHEMBL15226014 | 0.69 | HTT (0.68) | PKMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL8392709 | 0.69 | SMN1; SMN2 (0.96) | PKMSMN1; SMN2CTSSKMT2AHTT | |
| SCHEMBL12204063 | 0.69 | CTSS (0.59) | PKMSMN1; SMN2CTSSCTSLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729114-B2 | Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158018-A1 | Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S | CTSS, CTSV, CTSF | PKM 4748/4885SMN1; SMN2 2610/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.